Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
2e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human CD30, His Tag (Cat. No.CD0-HF2H4) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD30, His Tag (Cat. No. CD0-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Loaded Human CD30 Ligand, His Tag (Cat. No. CDL-H524b) on HIS1K Biosensor, can bind Human CD30 Protein, Llama IgG2b Fc Tag (Cat. No. TN8-H5250) with an affinity constant of 55.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Brentuximab vedotin | SGN-30; SGN-35; cAC-10; SGD-1010; cAC10-vcMMAE; cAC10-Val-Cit-MMAE | Approved | Millennium Pharmaceuticals Inc, Seagen Inc | Adcetris, 安适利 | United States | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Seagen Inc | 2011-08-19 | Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Sezary Syndrome; Lymphoma, T-Cell; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Leukemia, Mast-Cell; Scleroderma, Diffuse; Lymphoma, Non-Hodgkin; Hidradenitis Suppurativa; Mycosis Fungoides; Lymphomatoid Papulosis; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Graft vs Host Disease; Lymphoma, T-Cell, Peripheral; Solid tumours; Hematologic Neoplasms; HIV Infections; Lymphoma, B-Cell; Anemia, Refractory, with Excess of Blasts; Carcinoma; Hodgkin Disease; Hematologic Diseases; Mastocytosis, Systemic; Scleroderma, Systemic; Lymphoma, Large B-Cell, Diffuse; Enteropathy-Associated T-Cell Lymphoma; Neoplasms; Myelodysplastic Syndromes; Mesothelioma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides | Details |
| ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) | Phase 2 Clinical | Unc Lineberger Comprehensive Cancer Center | Lymphoma, T-Cell, Peripheral; Lymphatic Diseases; Immunoproliferative Disorders; Neoplasms; Hodgkin Disease; Immune System Diseases; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms, Germ Cell and Embryonal | Details | |
| Autologous CD30+ CAR T Cells therapy(New York Medical College) | Phase 2 Clinical | New York Medical College, University Of North Carolina At Chapel Hill | Hodgkin Disease | Details | |
| Itezocabtagene autoleucel | TT-11; TT11 | Phase 2 Clinical | Tessa Therapeutics Ltd | Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic | Details |
| BRD-01 | BRD-01 | Phase 2 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms; Hodgkin Disease | Details |
| GEN3017 | GEN-3017 | Phase 2 Clinical | Genmab A/S | Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Lymphoma, T-Cell, Cutaneous | Details | |
| HSP-CAR-30 | HSP-CAR-30 | Phase 2 Clinical | Fundació Institut De Recerca De L | Hodgkin Disease; Lymphoma, T-Cell | Details |
| Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) | CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta | Phase 2 Clinical | Pla General Hospital | Hodgkin Disease | Details |
| Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) | Phase 1 Clinical | Immune Cell Inc | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
| CD30.CAR-EBVST cell therapy (Baylor College of Medicine) | TT-11X | Phase 1 Clinical | Baylor College Of Medicine, Tessa Therapeutics Ltd | Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell | Details |
| EBV-specific-CAR.CD30 | EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System | Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
| Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Angioimmunoblastic T-cell Lymphoma | Details | |
| Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 | F0002-ADC; B-006(SCP) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details |
| CD30.CAR | H-27721; CD30.CAR | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin | Details |
| Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital) | Phase 1 Clinical | Shanghai Tongji Hospital | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma | Details | |
| CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
| SGN-35C | SGN-35C | Phase 1 Clinical | Seagen Inc | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma; Lymphoma, Large-Cell, Anaplastic | Details |
| SGN-35T | SGN-35T; SGN-CD30C; PF-08046045 | Phase 1 Clinical | Seagen Inc | Solid tumours; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous | Details |
| Anti-CD30 CAR T-cell therapy | Phase 1 Clinical | Minghui (Nanjing) Gene Biotechnology Co Ltd | Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
| Anti-CD30 CAR-T cell therapy (National Cancer Institute) | Hu30-CD28z | Phase 1 Clinical | National Cancer Institute | Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma | Details |
| PRA-052 | PRA-052 | Phase 1 Clinical | Prometheus Biosciences Inc | Colitis, Ulcerative | Details |
| SGN-CD30C | SGN-CD30C | Phase 1 Clinical | Seattle Genetics Inc | Lymphoma | Details |
| Anti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Hodgkin Disease | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
